E
ELucidata.io
Accelerating drug discovery by transforming the way data is used to drive decisions in RandD labs
About ELucidata.io
Elucidata is a biomedical data company founded in 2015, operating in the biotechnology and pharmaceutical sectors. The company focuses on making biomedical data more accessible and analysis-ready for drug discovery and research and development (R&D) purposes.
The core of its offering is Polly, an AI-powered, data-centric platform. Polly utilizes Bio-NLP (Natural Language Processing for Biology) technology to process and structure large volumes of biomedical data. The platform can handle various data types, including omics, clinical, and imaging data, by cleaning, curating, and harmonizing them from disparate sources. This process transforms the data into a state that is ready for machine learning applications, thereby accelerating research timelines.
The company's business model is centered around providing this platform to clients in early-stage R&D, precision medicine diagnostics, and translational research. By offering ML-ready data, Elucidata helps biotechnology and pharmaceutical companies to more rapidly identify biological targets and advance their drug development pipelines. The company is headquartered in Cambridge, MA, with a presence in San Francisco, CA.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- San Francisco, United States
- Employees
- 174
- Open positions
- 5
- Dealroom signal
- 74.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Tech for Biotech and Pharma, MLops, DT and LS
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2022 | $16M | $64M | F-Prime · Hyperplane VC · Eight Roads Ventures · IvyCap Ventures | ↗ |
| SEED✓Equity / VC | Jan 2021 | $5M | $20M | Hyperplane VC · IvyCap Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for ELucidata.io is 19K monthly website visits, up 46.2% over the last three months. ELucidata.io's team grew 6.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Hyperplane VC
IvyCap Ventures
Series A2 investors entered at this stage
Other known investors5 additional known investors
Yale University
Akshay Saxena- AVAnvaya Ventures
TiE SoCal Angels
Venkat Tadanki
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ELucidata.io on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ELucidata.io’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.